Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of chronic liver disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slows down further scarring of liver and results in improvement of the condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolution of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.  

Market Dynamics

The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase over the forecast period with increasing amount of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for these disorders. For instance, in April 2022, according to National Center for Biotechnology Information, the prevalence of NASH has significantly increased in the U.S. in the last decade. This is likely related to the increased prevalence of risk factors as well as increased awareness of the disease. The proportion of patients with NASH by gender was 54.1% female verses 45.9% male in 2021. Experts estimate about 24% of U.S. adults have Non-alcoholic fatty liver disease (NAFLD) and about 1.5% to 6.5% of U.S. adults have NASH. Non-alcoholic fatty liver disease (NAFLD) states as simple fat, which impacts on 20% to 30% of those individuals who progress to nonalcoholic steatohepatitis (NASH). Another 20% to 30% of individual’s progress to more advanced Non-alcoholic Steatohepatitis (NASH) fibrosis, and the final stage is Non-alcoholic Steatohepatitis (NASH) cirrhosis.

Key features of the study:

• This report provides an in-depth analysis of the global liver fibrosis treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global liver fibrosis treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver fibrosis treatment market

Detailed Segmentation:

• Global Liver Fibrosis Treatment, By Treatment Type :
  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
  • ACE Inhibitors
  • Hepatotropic Drug
  • Others
• Global Liver Fibrosis Treatment, By Condition:
  • Chronic Liver Diseases
  • Hepatitis C
  • Nonalcoholic Steatohepatitis
• Global Liver Fibrosis Treatment, By Distribution Channel:
  • Hospitals
  • Specialty Clinics
  • Others
• Global Liver Fibrosis Treatment, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Gilead Sciences, Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Johnson and Johnson
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • Pfizer Inc.
  • FibroGen, Inc.
  • Pharmaxis Limited

“*” marked represents similar segmentation in other categories in the respective section.